HPGC Renmintongtai Pharmaceutical Corp
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, and health products, as well as tonic health, daily necessities, and cosm… Read more
Market Cap & Net Worth: HPGC Renmintongtai Pharmaceutical Corp (600829)
HPGC Renmintongtai Pharmaceutical Corp (SHG:600829) has a market capitalization of $801.40 Million (CN¥5.88 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #14998 globally and #4001 in its home market, demonstrating a -2.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HPGC Renmintongtai Pharmaceutical Corp's stock price CN¥10.14 by its total outstanding shares 579888597 (579.89 Million).
HPGC Renmintongtai Pharmaceutical Corp Market Cap History: 2015 to 2026
HPGC Renmintongtai Pharmaceutical Corp's market capitalization history from 2015 to 2026. Data shows change from $1.19 Billion to $801.40 Million (-0.49% CAGR).
HPGC Renmintongtai Pharmaceutical Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HPGC Renmintongtai Pharmaceutical Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.06x
HPGC Renmintongtai Pharmaceutical Corp's market cap is 0.06 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.78x
HPGC Renmintongtai Pharmaceutical Corp's market cap is 2.78 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.19 Billion | $8.91 Billion | $138.92 Million | 0.13x | 8.56x |
| 2016 | $1.09 Billion | $9.01 Billion | $224.51 Million | 0.12x | 4.87x |
| 2017 | $906.70 Million | $8.01 Billion | $254.20 Million | 0.11x | 3.57x |
| 2018 | $451.99 Million | $7.06 Billion | $257.86 Million | 0.06x | 1.75x |
| 2019 | $528.74 Million | $8.35 Billion | $267.33 Million | 0.06x | 1.98x |
| 2020 | $575.26 Million | $8.01 Billion | $145.26 Million | 0.07x | 3.96x |
| 2021 | $531.11 Million | $9.32 Billion | $277.30 Million | 0.06x | 1.92x |
| 2022 | $504.23 Million | $9.64 Billion | $264.48 Million | 0.05x | 1.91x |
| 2023 | $618.04 Million | $10.39 Billion | $292.16 Million | 0.06x | 2.12x |
| 2024 | $592.75 Million | $10.05 Billion | $213.27 Million | 0.06x | 2.78x |
Competitor Companies of 600829 by Market Capitalization
Companies near HPGC Renmintongtai Pharmaceutical Corp in the global market cap rankings as of March 18, 2026.
Key companies related to HPGC Renmintongtai Pharmaceutical Corp by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
HPGC Renmintongtai Pharmaceutical Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, HPGC Renmintongtai Pharmaceutical Corp's market cap moved from $1.19 Billion to $ 801.40 Million, with a yearly change of -0.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥801.40 Million | -6.20% |
| 2025 | CN¥854.35 Million | +44.13% |
| 2024 | CN¥592.75 Million | -4.09% |
| 2023 | CN¥618.04 Million | +22.57% |
| 2022 | CN¥504.23 Million | -5.06% |
| 2021 | CN¥531.11 Million | -7.68% |
| 2020 | CN¥575.26 Million | +8.80% |
| 2019 | CN¥528.74 Million | +16.98% |
| 2018 | CN¥451.99 Million | -50.15% |
| 2017 | CN¥906.70 Million | -17.12% |
| 2016 | CN¥1.09 Billion | -8.01% |
| 2015 | CN¥1.19 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of HPGC Renmintongtai Pharmaceutical Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $801.40 Million USD |
| MoneyControl | $801.40 Million USD |
| MarketWatch | $801.40 Million USD |
| marketcap.company | $801.40 Million USD |
| Reuters | $801.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.